Boehringer Ingelheim, Quallent Pharmaceuticals Partner to Expand Access to Humira Biosimilar
Boehringer Ingelheim is partnering with Quallent Pharmaceuticals to help expand access to citrate-free adalimumab-adbm, Boehringer’s biosimilar to adalimumab (Humira), in the U.S. Under the terms of the agreement, Boehringer Ingelheim will manufacture adalimumab-adbm for Quallent. Boehringer Ingelheim will continue to commercialize Boehringer Ingelheim-labeled Cyltezo (adalimumab-adbm) injection and adalimumab-adbm. Quallent will be offering both high-concentration (40 […]